Screener
Xenon Pharmaceuticals XENE Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -43.6%-6.0pp | -37.5%-5.9pp | -51.8%-23.9pp | -45.1%-15.4pp | -37.6%-10.9pp | |
| Return on invested capital | -54%-2.0pp | -59.1%-18.3pp | -73.7%-34.2pp | -57.6%-17.3pp | -52%-15.7pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 21×+5.9× | 27.8×+10.1× | 13.4×-4.4× | 12.5×-9.7× | 15.1×-8.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $12.47+55.3% | $15.32+71.2% | $7.34-24.3% | $7.06-31.0% | $8.03-26.1% | |
| Valuation | ||||||
| Market capitalization | $6.24B+137% | $5.55B+116% | $3.46B+15.9% | $3.1B+1.2% | $2.47B-18.4% | |
| Price / book | 5×+0.9× | 4.1×+0.5× | 6×+2.0× | 5.5×+1.7× | 3.9×+0.3× |
FAQ
- Where do Xenon Pharmaceuticals's ratios come from?
- Every ratio is computed from Xenon Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.